Viatris Selling Its Biosimilars Business to Bangalore-Based Biocon for Up to $3.3B

By PacConAdmin | February 28, 2022

A biologics-focused subsidiary of Bangalore, India-based Biocon is buying the biosimilars portfolio of Pittsburgh, Pa.-based Viatris for up to $3.3 billion.
Source: Drug Industry Daily

Posted in Drug Industry Daily